Helping local pharma players make overseas foray


Duopharma Biotech Bhd group managing director Leonard Ariff Abdul Shatar (pic) said the MS:2424:2012 halal pharmaceuticals standard, which provides general guidelines in the manufacture and handling of halal pharmaceuticals, was rapidly gaining universal acceptance.

KUALA LUMPUR: Malaysia’s global leadership in setting standards for halal pharmaceuticals has served to facilitate the successful entry of domestic pharmaceutical manufacturers into the international halal pharmaceutical market, which is forecast to be valued at US$134bil by 2024.

Duopharma Biotech Bhd group managing director Leonard Ariff Abdul Shatar said the MS:2424:2012 halal pharmaceuticals standard, which provides general guidelines in the manufacture and handling of halal pharmaceuticals, was rapidly gaining universal acceptance.

Subscribe now and receive FREE sooka plan for 1 month.
T&C applies.

Monthly Plan

RM13.90/month

Annual Plan

RM12.33/month

Billed as RM148.00/year

1 month

Free Trial

For new subscribers only


Cancel anytime. No ads. Auto-renewal. Unlimited access to the web and app. Personalised features. Members rewards.
Follow us on our official WhatsApp channel for breaking news alerts and key updates!
   

Next In Business News

Asian currencies find support after volatile week, ringgit steady
Meta Bright's subsidiary bags concrete supply contract worth RM60mil
Cropmate aims to raise RM42mil from ACE Market IPO
Malaysia’s removal from US treasury monitoring list indicates balanced, transparent policies
Gold faces worst week in more than 3 years on bets of slower Fed easing
Malaysia's removal from US currency watch list affirms ringgit's market-driven status -Bank Negara Governor
China first to produce over 10m NEVs in a year
Bank Negara announces foreign exchange policy liberalisation for MDBs, qualified non-resident DFIs
Malaysian-led consortium makes offer for MAHB at RM11.00 per share
FBM KLCI slips below 1,600; GDP expands 5.3% in 3Q

Others Also Read